$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

$rnac Overview Financials Valuation SEC Filings Company Website

2018 Q1 Form 10-K Financial Statement

#000145368718000012 Filed on March 15, 2018

Income Statement

Concept	2018 Q1	2017 Q4	2017 Q3
Revenue	$0.00	$17.00K	$27.00K
YoY Change	-100.0%	-99.42%	-97.42%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.670M	$5.670M	$4.380M
YoY Change	20.36%	-1.56%	75.2%
% of Gross Profit
Research & Development	$11.14M	$13.62M	$9.504M
YoY Change	0.86%	23.48%	57.85%
% of Gross Profit
Depreciation & Amortization	$200.0K	$180.0K	$200.0K
YoY Change	0.0%	-28.0%	100.0%
% of Gross Profit
Operating Expenses	$15.81M	$19.29M	$13.88M
YoY Change	5.99%	14.91%	63.0%
Operating Profit	-$15.81M		-$13.85M
YoY Change	6.97%		85.51%
Interest Expense	$350.0K	-$130.0K	$268.0K
YoY Change	16.67%	-58.06%	-13.83%
% of Operating Profit
Other Income/Expense, Net	$0.00	-$140.0K	-$16.00K
YoY Change		-275.0%	-500.0%
Pretax Income	-$15.89M	-$19.54M	-$14.68M
YoY Change	5.02%	38.78%	89.91%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$15.89M	-$19.54M	-$14.68M
YoY Change	4.98%	38.78%	89.91%
Net Earnings / Revenue		-114964.71%	-54355.56%
Basic Earnings Per Share
Diluted Earnings Per Share	-$711.0K	-$876.6K	-$664.9K
COMMON SHARES
Basic Shares Outstanding	22.35M shares	22.34M shares	22.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q1	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$83.10M	$96.60M	$104.4M
YoY Change	21.31%	14.86%	31.65%
Cash & Equivalents	$58.23M	$70.62M	$72.15M
Short-Term Investments	$24.80M	$25.90M	$32.20M
Other Short-Term Assets	$1.900M	$2.100M	$3.000M
YoY Change	-34.48%	-16.0%	-16.67%
Inventory
Prepaid Expenses
Receivables	$63.00K	$63.00K	$0.00
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$98.68M	$98.68M	$107.4M
YoY Change	38.04%	13.67%	28.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.091M	$2.091M	$2.055M
YoY Change	1.8%	2.15%	-0.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.700M	$0.00	$0.00
YoY Change		-100.0%
Total Long-Term Assets	$2.420M	$2.420M	$2.371M
YoY Change	2.11%	-2.62%	-0.46%
TOTAL ASSETS
Total Short-Term Assets	$98.68M	$98.68M	$107.4M
Total Long-Term Assets	$2.420M	$2.420M	$2.371M
Total Assets	$101.1M	$101.1M	$109.7M
YoY Change	36.89%	13.21%	27.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.606M	$1.606M	$1.519M
YoY Change	21.94%	-58.63%	46.06%
Accrued Expenses	$8.580M	$8.580M	$6.547M
YoY Change	55.41%	118.82%	168.98%
Deferred Revenue	$787.0K	$787.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$10.97M	$10.97M	$11.32M
YoY Change	-17.52%	-19.94%	47.23%
LONG-TERM LIABILITIES
Long-Term Debt	$21.10M	$21.00M	$21.00M
YoY Change	205.8%	162.5%	130.77%
Other Long-Term Liabilities	$1.201M	$1.201M	$1.250M
YoY Change	-90.47%
Total Long-Term Liabilities	$1.201M	$1.201M	$1.250M
YoY Change	-93.84%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.97M	$10.97M	$11.32M
Total Long-Term Liabilities	$1.201M	$1.201M	$1.250M
Total Liabilities	$47.46M	$49.29M	$44.65M
YoY Change	44.83%	43.51%	119.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$215.1M	-$216.9M	-$197.4M
YoY Change	29.01%	43.07%	43.54%
Common Stock	$3.000K	$3.000K	$2.000K
YoY Change	200.0%	200.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$38.98M	$51.81M	$65.08M
YoY Change
Total Liabilities & Shareholders Equity	$101.1M	$101.1M	$109.7M
YoY Change	36.89%	13.21%	27.91%

Cashflow Statement

Concept	2018 Q1	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$15.89M	-$19.54M	-$14.68M
YoY Change	4.98%	38.78%	89.91%
Depreciation, Depletion And Amortization	$200.0K	$180.0K	$200.0K
YoY Change	0.0%	-28.0%	100.0%
Cash From Operating Activities	-$13.41M	-$12.67M	-$15.44M
YoY Change	-12.45%	-912.18%	182.27%
INVESTING ACTIVITIES
Capital Expenditures	$192.0K	-$150.0K	-$120.0K
YoY Change	231.03%	36.36%	-57.14%
Acquisitions
YoY Change
Other Investing Activities	$1.140M	$6.250M	-$2.240M
YoY Change	-106.92%	-222.79%	-88.77%
Cash From Investing Activities	$945.0K	$6.110M	-$2.380M
YoY Change	-105.72%	-217.5%	-88.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net	$0.00
YoY Change	-100.0%
Cash From Financing Activities	$51.00K	5.030M	7.340M
YoY Change	-117.47%	80.29%	211.02%
NET CHANGE
Cash From Operating Activities	-$13.41M	-12.67M	-15.44M
Cash From Investing Activities	$945.0K	6.110M	-2.380M
Cash From Financing Activities	$51.00K	5.030M	7.340M
Net Change In Cash	-$12.39M	-1.530M	-10.48M
YoY Change	-61.29%	80.0%	-55.06%
FREE CASH FLOW
Cash From Operating Activities	-$13.41M	-$12.67M	-$15.44M
Capital Expenditures	$192.0K	-$150.0K	-$120.0K
Free Cash Flow	-$13.60M	-$12.52M	-$15.32M
YoY Change	-11.53%	-849.7%	195.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q4
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001453687
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	22349840	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	287783534	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	SELECTA BIOSCIENCES INC
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2016Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	459000	USD
CY2017Q4	selb	Accrued Audit Fees Current AccruedAuditFeesCurrent	859000	USD
CY2016Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	0	USD
CY2017Q4	selb	Accrued Collaborationand Licensing AccruedCollaborationandLicensing	1020000	USD
CY2016Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	152000	USD
CY2017Q4	selb	Accrued Grant Refund Current AccruedGrantRefundCurrent	175000	USD
CY2016Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	415000	USD
CY2017Q4	selb	Accrued Patent Fees Current AccruedPatentFeesCurrent	268000	USD
CY2016Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	29000	USD
CY2017Q4	selb	Accrued Rent And Lease Incentive Payable Current AccruedRentAndLeaseIncentivePayableCurrent	72000	USD
CY2016Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	794000	USD
CY2017Q4	selb	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	3578000	USD
CY2017	selb	Debt Instrument Event Of Default Minimum Amount In Excess Of Indebtedness Trigger DebtInstrumentEventOfDefaultMinimumAmountInExcessOfIndebtednessTrigger	300000	USD
CY2017	selb	Debt Instrument Event Of Default Minimum Assets Trigger DebtInstrumentEventOfDefaultMinimumAssetsTrigger	300000	USD
CY2016Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	300000	USD
CY2017Q4	selb	Deferred Rent And Lease Incentive Liability DeferredRentAndLeaseIncentiveLiability	200000	USD
CY2016Q4	selb	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	52905000	USD
CY2017Q4	selb	Deferred Tax Assets Net Of Deferred Tax Liabilities DeferredTaxAssetsNetOfDeferredTaxLiabilities	57637000	USD
CY2015	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-805000	USD
CY2016	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	-461000	USD
CY2017	selb	Increase Decrease In Contingently Repayable Grant Funding IncreaseDecreaseInContingentlyRepayableGrantFunding	0	USD
CY2015	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	1246000	USD
CY2016	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	122000	USD
CY2017	selb	Initial Public Offering Costs Incurred But Not Yet Paid InitialPublicOfferingCostsIncurredButNotYetPaid	0	USD
CY2015	selb	Noncash Investing And Financing Activities Issuance Of Preferred Warrants In Connection With Venture Loans NoncashInvestingAndFinancingActivitiesIssuanceOfPreferredWarrantsInConnectionWithVentureLoans	137000	USD
CY2016	selb	Noncash Investing And Financing Activities Issuance Of Preferred Warrants In Connection With Venture Loans NoncashInvestingAndFinancingActivitiesIssuanceOfPreferredWarrantsInConnectionWithVentureLoans	0	USD
CY2017	selb	Noncash Investing And Financing Activities Issuance Of Preferred Warrants In Connection With Venture Loans NoncashInvestingAndFinancingActivitiesIssuanceOfPreferredWarrantsInConnectionWithVentureLoans	0	USD
CY2015	selb	Noncash Investing And Financing Activities Venture Debt Termination Fee Liability NoncashInvestingAndFinancingActivitiesVentureDebtTerminationFeeLiability	270000	USD
CY2016	selb	Noncash Investing And Financing Activities Venture Debt Termination Fee Liability NoncashInvestingAndFinancingActivitiesVentureDebtTerminationFeeLiability	0	USD
CY2017	selb	Noncash Investing And Financing Activities Venture Debt Termination Fee Liability NoncashInvestingAndFinancingActivitiesVentureDebtTerminationFeeLiability	0	USD
CY2015	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	0	USD
CY2016	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	4404000	USD
CY2017	selb	Noncash Or Partial Noncash Reclassification Of Deferred Ipo Costs From Non Current Assets To Additional Paid In Capital NoncashOrPartialNoncashReclassificationOfDeferredIpoCostsFromNonCurrentAssetsToAdditionalPaidInCapital	0	USD
CY2017	selb	Stock Issued During Period Value Conversion Preferred Stock Warrants StockIssuedDuringPeriodValueConversionPreferredStockWarrants	47115000	USD
CY2016	selb	Stock Issued During The Period Value Warrants Exercised StockIssuedDuringThePeriodValueWarrantsExercised	0	USD
CY2015	selb	Stock Vested During Period Value Restricted Common Stock StockVestedDuringPeriodValueRestrictedCommonStock	23000	USD
CY2016	selb	Stock Vested During Period Value Restricted Common Stock StockVestedDuringPeriodValueRestrictedCommonStock	21000	USD
CY2015	selb	Stockholders Equity Accretion To Redemption Value StockholdersEquityAccretionToRedemptionValue	7335000	USD
CY2016	selb	Stockholders Equity Accretion To Redemption Value StockholdersEquityAccretionToRedemptionValue	4566000	USD
CY2017	selb	Tax Cutsand Jobs Act Changein Tax Rate Increase Decrease In Deferred Tax Asset TaxCutsandJobsActChangeinTaxRateIncreaseDecreaseInDeferredTaxAsset	-23400000	USD
CY2017	selb	Tax Cutsand Jobs Act Valuation Allowance Deferred Tax Asset Increase Decrease Amount TaxCutsandJobsActValuationAllowanceDeferredTaxAssetIncreaseDecreaseAmount	23400000	USD
CY2017Q4	selb	Votes Per Shareof Common Stock VotesPerShareofCommonStock	1
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3882000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1606000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	215000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	63000	USD
CY2015	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2016	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-193000	USD
CY2017	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-233000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3921000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8580000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3740000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4158000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4518000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4420000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	211125000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	273128000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1125000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2030000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4080000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1125000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2051000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4081000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12137409	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2225648	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2833619	shares
CY2017Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	5100	sqft
CY2016Q4	us-gaap	Assets Assets	89301000	USD
CY2017Q4	us-gaap	Assets Assets	101100000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	86816000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	98680000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	24785000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	25940000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	53000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	16000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	24821000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	25956000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	13200000	USD
CY2017Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	12800000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	24821000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Amortized Cost AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost	25956000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	24785000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	25940000	USD
CY2017Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	8	position
CY2017Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions1 AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1	12	position
CY2015	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	147000	USD
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	103000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16592000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32337000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58656000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	70622000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15745000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	26319000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11966000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3164965	shares
CY2017Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	3757059	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18438742	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	22343254	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18438742	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	22343254	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	1000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26284000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-35742000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65223000	USD
CY2016Q2	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	10126118	shares
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7288000	USD
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2017Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.0653
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	1725000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	108000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	222000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	151000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1836000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	787000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	12439000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	15919000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5607000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	4021000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4934000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	4264000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	54630000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57745000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39420000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44146000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	3052000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4092000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	904000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	959000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	713000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	263000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	52905000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	57637000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	69000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	131000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	108000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	1525000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Unrealized Currency Transaction Gains DeferredTaxLiabilitiesUnrealizedCurrencyTransactionGains	0	USD
CY2015	us-gaap	Depreciation Depreciation	1000000	USD
CY2015	us-gaap	Depreciation Depreciation	1044000	USD
CY2016	us-gaap	Depreciation Depreciation	802000	USD
CY2016	us-gaap	Depreciation Depreciation	800000	USD
CY2017	us-gaap	Depreciation Depreciation	800000	USD
CY2017	us-gaap	Depreciation Depreciation	750000	USD
CY2017	us-gaap	Dividends Common Stock DividendsCommonStock	0	USD
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-4.52
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.75
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-15.13
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.77
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.89
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.82
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.85
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
CY2017Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.88
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.20
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-1019000	USD
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	443000	USD
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	78000	USD
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.000
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.400
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.398
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.067
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	-0.358
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.007
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.011
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.000
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.023
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.057
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.058
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.058
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.010
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.013
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.005
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1551000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1902000	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-83000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	12000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	933000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-525000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-123000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-36000	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2327000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	153000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-610000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-152000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1259000	USD
CY2016	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	716000	USD
CY2017	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	5650000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-507000	USD
CY2016	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10409000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2432000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1011000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	860000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-673000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8335000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13051000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18826000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	667000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2686000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-525000	USD
CY2015	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-977000	USD
CY2016	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-103000	USD
CY2017	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-689000	USD
CY2015	us-gaap	Interest Expense InterestExpense	948000	USD
CY2016	us-gaap	Interest Expense InterestExpense	1253000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1206000	USD
CY2015	us-gaap	Interest Paid InterestPaid	531000	USD
CY2016	us-gaap	Interest Paid InterestPaid	972000	USD
CY2017	us-gaap	Interest Paid InterestPaid	905000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81000	USD
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	89000	USD
CY2015	us-gaap	Investment Income Net InvestmentIncomeNet	171000	USD
CY2016	us-gaap	Investment Income Net InvestmentIncomeNet	234000	USD
CY2017	us-gaap	Investment Income Net InvestmentIncomeNet	617000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	34344000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	49286000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89301000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101100000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13706000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10973000	USD
CY2016Q4	us-gaap	Loans Payable Current LoansPayableCurrent	4067000	USD
CY2017Q4	us-gaap	Loans Payable Current LoansPayableCurrent	0	USD
CY2016Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	7977000	USD
CY2017Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	21042000	USD
CY2015	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	0	USD
CY2016	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-36000	USD
CY2017	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	20000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19683000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52037000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43906000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67659000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	66023000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4679000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22100000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2098000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-22463000	USD
CY2016Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9133000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-25174000	USD
CY2016Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7728000	USD
CY2016Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14083000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40776000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-7476000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-6923000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-7728000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-14083000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-36210000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-15134000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-15967000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-14676000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-19544000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-65321000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32509000	USD
CY2016Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9832000	USD
CY2017Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15134000	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-15967000	USD
CY2017Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14676000	USD
CY2017Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19544000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-65321000	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2015	us-gaap	Operating Expenses OperatingExpenses	31315000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	9029000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	8418000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	8516000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	16790000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	42753000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	14919000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	15897000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	13881000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	19294000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	63991000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-25304000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-34670000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-63784000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3294000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1437000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	375000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	1482000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1100000	USD
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1600000	USD
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1900000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	440000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	617000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	122000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2015	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1110000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	504000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	78000	USD
CY2015	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2016	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-36000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	20000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1201000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-26000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-152000	USD
CY2017	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2015	us-gaap	Paid In Kind Interest PaidInKindInterest	198000	USD
CY2016	us-gaap	Paid In Kind Interest PaidInKindInterest	263000	USD
CY2017	us-gaap	Paid In Kind Interest PaidInKindInterest	390000	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	302000	USD
CY2016	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	4103000	USD
CY2017	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1163000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	586000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	733000	USD
CY2015	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	3516000	USD
CY2016	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	28416000	USD
CY2017	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	61527000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2382000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1979000	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	7092000	USD
CY2016	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2017	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2015	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2016	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	68870000	USD
CY2017	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2743000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10000000	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	32669000	USD
CY2016	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2016	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	47114000	USD
CY2015	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	6674000	USD
CY2016	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	USD
CY2017	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	20957000	USD
CY2015	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	0	USD
CY2016	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	64465000	USD
CY2016	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	2743000	USD
CY2017	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	10000000	USD
CY2015	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	7335000	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	86000	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	109000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	149000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	149000	USD
CY2016	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	6900000	USD
CY2017	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	60158000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	706000	USD
CY2015	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2016	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	4566000	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	705000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-87755000	USD
CY2016	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	0	USD
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	180000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5787000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6249000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2047000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2091000	USD
CY2017	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2016Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	75000	USD
CY2017Q4	us-gaap	Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock ReceivableFromShareholdersOrAffiliatesForIssuanceOfCapitalStock	0	USD
CY2015	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2336000	USD
CY2016	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	12934000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22980000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29702000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45165000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	78000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	76000	USD
CY2016Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	316000	USD
CY2017Q4	us-gaap	Restricted Cash And Investments Noncurrent RestrictedCashAndInvestmentsNoncurrent	329000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151576000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-151600000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216900000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-216897000	USD
CY2015	us-gaap	Revenues Revenues	6011000	USD
CY2016Q1	us-gaap	Revenues Revenues	2088000	USD
CY2016Q2	us-gaap	Revenues Revenues	2017000	USD
CY2016Q3	us-gaap	Revenues Revenues	1048000	USD
CY2016Q4	us-gaap	Revenues Revenues	2930000	USD
CY2016	us-gaap	Revenues Revenues	8083000	USD
CY2017Q1	us-gaap	Revenues Revenues	137000	USD
CY2017Q2	us-gaap	Revenues Revenues	26000	USD
CY2017Q3	us-gaap	Revenues Revenues	27000	USD
CY2017Q4	us-gaap	Revenues Revenues	17000	USD
CY2017	us-gaap	Revenues Revenues	207000	USD
CY2017	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	22343254	shares
CY2016Q4	us-gaap	Short Term Investments ShortTermInvestments	25485000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	25940000	USD
CY2015	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants	3647000	USD
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	142048000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	180000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	-116493000	USD
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14400000	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4700000	USD
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	2150422	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10493939	shares
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20425050	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	54957000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	51814000	USD
CY2016Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	3.9
CY2016Q1	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2356000	USD
CY2016Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	2210000	USD
CY2016Q3	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2016Q4	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2016	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	4566000	USD
CY2017	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	USD
CY2017	us-gaap	Temporary Equity Accretion To Redemption Value TemporaryEquityAccretionToRedemptionValue	0	USD
CY2015	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	7335000	USD
CY2014Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2015Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	0	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2015Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	37835623	shares
CY2015	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	0	USD
CY2017	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Concentrations of Credit Risk and Off‑Balance Sheet Risk</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and accounts receivable. Cash and cash equivalents are deposited with federally insured financial institutions in the United States and may, at times, exceed federally insured limits. Management believes that the financial institutions that hold the Company’s deposits are financially credit worthy and, accordingly, minimal risk exists with respect to those balances. Generally, these deposits may be redeemed upon demand and therefore bear minimal interest rate risk. As an integral part of operating its Russian subsidiary, the Company also maintains cash in Russian bank accounts in denominations of both Russian rubles and U.S. dollars. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company maintained approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> in Russian bank accounts, of which </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> was held in U.S. dollars.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has minimal credit risk as the majority of accounts receivable relates to amounts due under a government sponsored grant, collaboration with large pharmaceutical companies or grants from well‑known and supported non‑profit organizations. The Company did not have any off balance sheet arrangements as of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Use of Estimates</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company’s management considers many factors in selecting appropriate financial accounting policies and controls, and bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. In preparing these consolidated financial statements, management used significant estimates in the following areas, among others: revenue recognition, the fair value of common stock and other equity instruments, accounting for stock-based compensation and estimating accrued research and development expenses. The Company assesses the above estimates on an ongoing basis; however, actual results could materially differ from those estimates.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s management made significant estimates and assumptions in determining the fair value of its common stock for those periods reported prior to the completion of the initial public offering of the Company’s common stock (the “IPO”). The Company utilized various valuation methodologies in accordance with the framework of the 2004 American Institute of Certified Public Accountants’ Technical Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, to estimate the fair value of its common stock. Each valuation methodology included estimates and assumptions that require the Company’s judgment. These estimates and assumptions included a number of objective and subjective factors, including external market conditions affecting the biotechnology industry sector, the prices at which the Company sold shares of its preferred stock, the superior rights and preferences of securities senior to the Company’s common stock at the time and the likelihood of achieving a liquidity event, such as an initial public offering or sale. Significant changes to the key assumptions used in the valuations could result in different fair values of common stock at each valuation date.</font></div></div>

Files In Submission

Name	View Source	Status
0001453687-18-000012-index-headers.html	Edgar Link	pending
0001453687-18-000012-index.html	Edgar Link	pending
0001453687-18-000012.txt	Edgar Link	pending
0001453687-18-000012-xbrl.zip	Edgar Link	pending
exhibit231_123117.htm	Edgar Link	pending
exhibit311_123117.htm	Edgar Link	pending
exhibit312_123117.htm	Edgar Link	pending
exhibit321_123117.htm	Edgar Link	pending
exhibit322_123117.htm	Edgar Link	pending
figure1a03.jpg	Edgar Link	pending
figure3a01.jpg	Edgar Link	pending
figure4a03.jpg	Edgar Link	pending
figure59.jpg	Edgar Link	pending
figure63.jpg	Edgar Link	pending
figure66.jpg	Edgar Link	pending
figure69.jpg	Edgar Link	pending
figure72.jpg	Edgar Link	pending
figure75.jpg	Edgar Link	pending
figure85.jpg	Edgar Link	pending
figure9a01.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipelinediagram002.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
report.css	Edgar Link	pending
selb-20171231.xml	Edgar Link	completed
selb-20171231.xsd	Edgar Link	pending
selb-20171231_cal.xml	Edgar Link	unprocessable
selb-20171231_def.xml	Edgar Link	unprocessable
selb-20171231_lab.xml	Edgar Link	unprocessable
selb-20171231_pre.xml	Edgar Link	unprocessable
selectabiosciences10-k1231.htm	Edgar Link	pending
Show.js	Edgar Link	pending
slide1.jpg	Edgar Link	pending
slide1a04.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac

2018 Q1 Form 10-K Financial Statement

#000145368718000012 Filed on March 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC Cartesian Therapeutics, Inc. Stock $rnac

2018 Q1 Form 10-K Financial Statement

#000145368718000012 Filed on March 15, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNAC
Cartesian Therapeutics, Inc. Stock $rnac